| Name | Title | Contact Details |
|---|
Health Systems International is focused on healthcare affordability for our clients. Our goal is to ensure each interaction is paid at the most affordable amount for all involved. We do this through a set of Payment Integrity Solutions built on our data analytics, cloud-based, multi sided business platform and expertise in Provider and Network Data Management. Our solution set is designed to improve efficiencies, reduce cost, and provide insight though a unique set of prevention, prepayment and post payment solutions. Our company has a rich history in providing cost savings to multiple markets across the healthcare eco-system. Regardless of your specific market segment, be it a Payor, Health plan, TPA, P&C Carrier, Workers’ Compensation Administrator, PBM, HIE or ACO, you want to ensure the reimbursements paid by you and your members are accurate, appropriate, and at the most affordable rate. That is our focus! We bring decades of expertise, a commitment to information and analytics, and most importantly a culture that is dedicated and aligned to creating value for our customers and partners alike.
Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.
Business Health Services is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.
Gen-Diagnostics Incorporated is a San Juan Capistrano, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.